Janssen has offered England and Scotland the chance to prescribe hepatitis C drug Olysio (simeprevir) on the National Health Service, and only pay for it in those patients who clear the virus within 12 weeks. Janssen's timing coincides with growing competition in the HCV space, and may be a way of fending off rivalry from Gilead's Harvoni (sofosbuvir and ledipasvir).
Janssen has offered England and Scotland the chance to prescribe hepatitis C drug Olysio (simeprevir) on the National Health Service, and only pay for it in those patients who clear the virus within 12 weeks. Janssen's timing coincides with growing competition in the HCV space, and may be a way of fending off rivalry from Gilead's Harvoni (sofosbuvir and ledipasvir).
As a way of managing the scheme, the company will fund pre-treatment blood tests for patients that can predict whether...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
